Company news

Trevi Therapeutics, Inc. news in 2025

Trevi Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

December 3, 2025

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 12, 2025

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

November 5, 2025

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

November 3, 2025

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

October 7, 2025

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

September 17, 2025

Trevi Therapeutics to Participate in Upcoming September Conferences

August 27, 2025

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6, 2025

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

July 30, 2025

Trevi Therapeutics to Participate in Upcoming August Conferences

July 28, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

June 30, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 4, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 2, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 1, 2025

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 31, 2025

Trevi Therapeutics to Participate in Upcoming June Conferences

May 28, 2025

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 19, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

April 30, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

April 2, 2025

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

March 17, 2025

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

March 10, 2025

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

March 9, 2025

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

March 8, 2025

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

February 26, 2025

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

February 24, 2025

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

January 29, 2025

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

January 7, 2025

Calls in 2025

Decks in 2025